Format

Send to

Choose Destination
J Med Chem. 2015 Jan 8;58(1):96-110. doi: 10.1021/jm5016044. Epub 2014 Dec 5.

Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

Author information

1
Nimbus Discovery , 25 First Street, Suite 404, Cambridge, Massachusetts 02141, United States.

Abstract

IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncology diseases. Herein, we summarize the compelling biology surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clinically viable IRAK4 inhibitors. Finally, a view of knowledge gained and remaining challenges is provided.

PMID:
25479567
DOI:
10.1021/jm5016044
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center